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Abstract
In 50% of progressing HIV-1 patients, CXCR4-tropic (X4) virus emerges late in infection, often overtaking CCR5-tropic (R5)
virus as the dominant viral strain. This ‘‘phenotypic switch’’ is strongly associated with rapidly declining CD4
+ T cell counts
and AIDS onset, yet its causes remain unknown. Here, we analyze a mathematical model for the mechanism of X4
emergence in late-stage HIV infection and use this analysis to evaluate the utility of a promising new class of antiretroviral
drugs—CCR5 inhibitors—in dual R5, X4 infection. The model shows that the R5-to-X4 switch occurs as CD4
+ T cell activation
levels increase above a threshold and as CD4
+ T cell counts decrease below a threshold during late-stage HIV infection.
Importantly, the model also shows that highly active antiretroviral therapy (HAART) can inhibit X4 emergence but that
monotherapy with CCR5 blockers can accelerate X4 onset and immunodeficiency if X4 infection of memory CD4
+ T cells
occurs at a high rate. Fortunately, when CXCR4 blockers or HAART are used in conjunction with CCR5 blockers, this risk of
accelerated immunodeficiency is eliminated. The results suggest that CCR5 blockers will be more effective when used in
combination with CXCR4 blockers and caution against CCR5 blockers in the absence of an effective HAART regimen or
during HAART failure.
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Introduction
Left untreated, human immunodeficiency virus type-1 (HIV)
generally targets and severely depletes a patient’s CD4
+ T cells over
a period of up to 15 years, with a median AIDS onset time of 9.8
years [1–4]. HIV’s infection of a CD4
+ T cell begins when HIV’s
outer envelope protein gp120 binds to a CD4 receptor and
subsequently binds to one of two chemokine coreceptors, CCR5 or
CXCR4 [5,6]. Viral-coreceptor binding exposes a second viral
envelope protein, gp41, which mediates fusion of the viral and
target-cell membranes, allowing HIV to inject its retroviral material
into the cell. HIV strains that use CCR5 as a coreceptor are termed
R5 viruses, while those that bind CXCR4 are called X4 viruses.
R5 virus is predominant during early infection where X4 virus
has rarely been observed, independent of the route of viral
transmission [5,7–9]. Importantly, X4 alone is generally unable to
infect humans: individuals homozygous for a 32 base-pair deletion
in CCR5, CCR5D32, are almost entirely immune to HIV [5].
However, in approximately 50% of progressing HIV patients, a
‘phenotypic switch’ occurs wherein X4 virus emerges late in
infection, overtaking R5 virus as the dominant viral strain. The
R5-to-X4 switch is strongly associated with a poor clinical
prognosis for the patient: it occurs with a steep loss in CD4
+ T
cell counts and accelerated AIDS onset.
The mechanisms causing R5’s early dominance and the
subsequent R5-to-X4 switch are poorly understood, however
multiple lines of evidence suggest that CCR5’s higher cell-surface
density on activated and recently activated memory CD4
+ T cells
enable R5 to infect more of this crucial cellular population than
X4. CCR5’s cell-surface density has been shown to determine the
efficiency of R5 infection [10], possibly because multiple CCR5
receptors act in a cooperative, concentration-dependent manner
to facilitate infection [11]. R5 virus’ level of infection is thus
highest among CD62L
2 effector memory CD4
+ T cells [12],
where CCR5’s cell surface density is highest. CXCR4’s cell-
surface density is similarly positively correlated with X4’s
emergence [13], but CXCR4’s per-cell density on memory
CD4
+ T cells is lower than that of CCR5 [14], giving R5 an
advantage on these cells. On dually-positive CCR5
+, CXCR4
+
CD4
+ T cells, the coreceptors compete for association with CD4
[15], which should lend R5 an advantage given CCR5’s higher
per-cell surface density on dually-positive cells [14].
Thus, R5 virus’ early advantage may stem from CCR5’s greater
per-cell surface density on activated and recently activated ‘effector’
memory CD4
+ T cells [14,15]. These ‘effector’ memory CD4
+ T
cells are the crucial virion-producing populations as evidenced by
snapshots taken during SIV infection, which show approximately
five times as many virions surrounding infected, activated effector
memory CD4
+ T cells as around infected, quiescent CD4
+ T cells
[16]. Moreover, Li et al. show that CD4
+ T cells positive for Ki67
(a marker that is displayed after late G1 cell-cycle progression and
indicates T cell ‘activation’) produce over 90% of the virions
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explain why X4 has trouble initiating infection when R5 virus is
absent: CXCR4’s per-cell density on the most crucial memory
CD4
+ T cell population is simply too low [14].
The perplexing question underlying the R5-to-X4 phenotypic switch is
therefore: how does a switch to X4 occur if R5 virus is simply better at infecting
memory CD4
+ T cells?
Since the R5-to-X4 switch only occurs during late infection, it is
reasonable that there exists an early selection pressure in favor of
R5 virus, which is mitigated over the course of infection. In
support of this hypothesis, Ribeiro and colleagues recently
proposed the idea that increasing target-cell activation over the
course of dual infection causes X4 to eventually outcompete R5
[18].
A critical prediction of the Ribeiro model is that CCR5 blockers
(small-molecule pharmaceuticals that bind CCR5 and thereby
obstruct R5 virus’ ability to infect a CD4
+ T cell) successfully
reduce overall viral loads, decrease cellular activation levels, and
inhibit X4 emergence. This prediction is critical since a central
question is whether CCR5 blockers lend X4 virus an advantage
and promote clinically deleterious switches to X4 during dual R5
and X4 infection. However, in vivo trials of the CCR5 inhibitors
CMPD 167 and maraviroc showed CCR5 blockers actually
increasing X4 viral loads and decreasing R5 viral loads
(approximately reciprocally) in dually-infected patients [19,20].
Given the recent CCR5 clinical trial data, we analytically
probed how changing target cell activation levels could produce a
switch and whether such models could account for documented
increases in X4 viral load after anti-CCR5 treatment. Our model
builds upon [18], but in our generalized setup the R5-to-X4 switch
can occur even if the fraction of activated naı ¨ve CD4
+ T cells
increases at a slower rate than the fraction of activated memory
CD4
+ T cells. In this more general setting, we rigorously show how
the R5 to X4 switch occurs and find that CCR5 blockers often do
accelerate X4’s emergence and attendant immunodeficiency.
Fortunately, the results also show that when CXCR4 inhibitors
or HAART are given along with CCR5 inhibitors, X4 emergence
is unlikely to be accelerated and is instead often delayed.
Models
In the following three models, all variables are capitalized and
represent concentrations per microliter (1/ml). Specifically, in
Model 1, T represents the concentration of uninfected CD4
+ T
cells, and (without loss of generality) is given an initial value of
1000 CD4
+ T cells/ml. In Models 2 and 3, T is split into uninfected
naı ¨ve (N) and memory (M) subpopulations, each with an initial
value of 500 CD4
+ T cells/ml. I4 and I5 reflect the concentrations
of abortively, latently, and productively infected CD4
+ T cells by X4 and
R5, respectively, and in Model 3, we analogously define N4,M 4,
M5 (see below). V4 and V5, each given initial values of 1000
virions/ml, represent X4 and R5 viral load concentrations.
Defining the parameters, l is the rate of thymus production of
CD4
+ T cells and has units cells/(mlNday), k4 and k5 are the
respective infection rate coefficients for X4 and R5 infection of
CD4
+ T cells and have the units ml/(virionsNday). All remaining
parameters have units 1/day. These include: dT, the death rate of
uninfected CD4
+ T cells in Model 1, set to l/T0 to allow for
steady-state pre-infection, and dn and dm the analogous death rates
of uninfected CD4
+ T cells in Models 2 and 3, also set so that
equilibrium exists pre-infection. Additionally, d is the death rate of
infected CD4
+ T cells, p is the rate of viral production by activated
infected cells, and c is the viral clearance rate. an and am are
required to satisfy Equation 2 (below) and represent the fractions
of activated naı ¨ve and memory CD4
+ T cells as a function of CD4,
the total number of uninfected and infected CD4
+ T cells per
microliter. Thus, in Models 1 and 2, CD4=T+I4+I5, and,
analogously, in Model 3 CD4=N+M+N4+M4+M5. Since the total
concentration of CD4
+ T cells changes over time, an and am vary
over the course of infection.
Because over 99% of infected cells are defectively infected [21]
and because such non-productively infected cells are indistin-
guishable from uninfected cells, we make the simplifying
assumption that an and am also approximate the fractions of infected
naı ¨ve and memory CD4
+ T cells that are activated. Thus, in
Models 1 and 2, anI4 and amI5 represent the concentrations of
activated X4 and R5 infected cells, respectively. Analogously, in
Model 3, anN4,a mM4, and amM5 represent the concentrations of
activated X4-infected naı ¨ve, X4-infected memory, and R5-infected
memory CD4
+ T cells, respectively. In our models, it is only these
activated subpopulations of infected cells that produce virions. We
thus multiply the concentration of activated infected cells (e.g.,
amM5)b yp, the rate of viral production (per-day) from a
productively-infected (i.e., activated and infected) cell, yielding the
respective total concentration of virions produced each day by a
given infected cell type.
Model 1: Single Target Cell Compartment
We first extended the basic model of viral dynamics [1,2] to two
viral strains, to test whether this simplified, one-compartment
model can generate a representative R5-to-X4 switch.
_ T T~l{(k4V4zk5V5)T{dTT
_ I I4~k4V4T{dI4
_ I I5~k5V5T{dI5
_ V V4~panI4{cV4
_ V V5~pamI5{cV5
ðModel 1Þ
Here we make X4’s viral production dependent on the fraction
of activated naı ¨ve CD4
+ Tc e l l san,b u tn o to nam.O n er e a s o nf o r
Author Summary
HIV has caused over 30 million deaths. The virus is so fatal
because it infects and depletes CD4
+ T cells, ‘‘helper’’
immune cells critical for orchestrating and stimulating the
overall immune response. No one understands why, in
about 50% of HIV infections, a more deadly strain emerges
late in infection. The new HIV strain, known as X4, differs
from its predecessor, known as R5, because X4 only infects
CD4
+ T cells displaying the receptor CXCR4, while R5 only
infects CD4
+ T cells displaying the receptor CCR5. Because
CXCR4 and CCR5 are found on different CD4
+ T cells, X4
depletes a second set of critical immune cells, accelerating
immunodeficiency and death. Recently, the FDA began
approving drugs that selectively block R5, and some
researchers have touted anti-R5 therapy alone as a
potentially safer alternative to current anti-HIV drugs. But
an open question is whether anti-R5 treatments push HIV
toward the more deadly X4 variant earlier. To understand
how X4 emerges and how anti-R5 treatments affect X4, we
apply a combination of mathematical analysis and
simulation. An important medical result of our work is
that anti-R5 treatment alone can accelerate X4 emergence
and immunodeficiency. Our results suggest that anti-R5
treatment only be used with anti-X4 treatment or anti-HIV
drug ‘‘cocktails,’’ which combat R5 and X4 equally.
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positive memory CD4
+ Tc e l l s[ 2 2 ] .F u r t h e r m o r e ,t h ev a s t
majority of CXCR4-positive T cells are in the naı ¨ve subset,
where CXCR4’s cell surface density is also highest [14]. Since
Model 1 lumps all CD4
+ T cells into a single target-cell
compartment, and because across all lymphocytes CXCR4’s
median per-cell surface density is almost three times as high as
that of CCR5 [14], we also assume k4.k5.A sa b o v e ,t h i sd o e s
not imply that X4 productively infects more target cells than R5 at
the beginning of infection, since very few naı ¨ve cells are
activated early in infection [23]. Importantly, given the
simplifications employed, the purpose of Model 1 is not to
represent the actual dynamics of coreceptor tropism in HIV
infection, but to rigorously explore an activation-based R5 to
X4 switch in the simplest setting.
Model 2: Two Target Cell Compartments
To account for the fact that in reality naı ¨ve and memory CD4
+
T cells are disjoint target cell compartments, we subsequently
build upon Model I and divide T into N and M.
_ N N~lz(1{2f)anN{k4V4N{dNN
_ M M~2fanNzamM{k5V5M{dMM
_ I I4~k4V4N{dI4
_ I I5~k5V5M{dI5
_ V V4~panI4{cV4
_ V V5~pamI5{cV5
ðModel 2Þ
The equations in this system are analogous to those in Model 1
but the uninfected CD4
+ T cell population is now split into
uninfected naı ¨ve (N) and memory (M) subpopulations. Addi-
tionally, f is defined to be the fraction of naı ¨ve cells activated via
the conventional Ag-TCR interaction, which divide and
differentiate into CD45RO
+ memory cells. The rest of the
activated cells are assumed to have been upregulated via
cytokines or other Ag-TCR independent processes and thus
remain phenotypically naı ¨ve (CD45RA
+) [24–26]. We note that
non-Ag mediated activation of naı ¨ve CD4
+ T cells is not
absolutely necessary for our models’ primary conclusions of
strain coexistence and phenotypic switching at clinically-
representative time-points (i.e., 3–6 years post-infection); we
include this activation term for the added realism it brings to the
model.
In Model 2, X4 is only able to infect naı ¨ve CD4
+ Tc e l l s ,a
simplification we employ because of the data in [14] showing that
the per-cell density of CCR5 is significantly higher than that of
CXCR4 on memory CD4
+ T cells. Moreover, a recent paper
finds that on dually-positive CXCR4
+, CCR5
+ CD4
+ T cells, R5
generally outcompetes X4 [22], arguably because of CCR5’s
higher surface density [15]. Finally, naı ¨ve CD4
+ Tc e l l sh a v e
been found to be preferentially depleted during X4 infection
[27].
Model 3: Two Target Cell Compartments with Viral
Competition
Because in practice X4 actually infects both naı ¨ve and memory
CD4
+ T cells, in our final model, Model 3, we extend the two-
compartment setup of Model 2 to allow X4’s infection of memory
CD4
+ T cells:
_ N N~lz(1{2f)anN{kN4V4N{dNN
_ M M~2fanNzamM{kM4V4M{kM5V5M{dMM
_ N N4~kN4V4N{dN4
_ M M4~kM4V4M{dM4
_ M M5~kM5V5M{dM5
_ V V4~p(anN4zamM4){cV4
_ V V5~pamM5{cV5
ðModel 3Þ
In this model, kN4 and kM4 are the infection rate coefficients of X4
on naı ¨ve (N) and memory (M) CD4
+ T cells, respectively, and kM5
is the infection rate coefficient of R5 on memory CD4
+ T cells.
kN4,k M4, and kM5 all have units ml/(virionsNday). N4 and M4 are
the concentrations of abortively, latently, and productively infected naı ¨ve
and memory CD4
+ T cells, respectively, by X4 virus, and M5 is
the concentration of abortively, latently, and productively infected
memory CD4
+ T cells by R5 virus. All other parameters, variables,
and initial conditions have been defined above. Because CCR5 is
far more strongly expressed on memory CD4
+ T cells than is
CXCR4 [14], we set kM5&kM4. Conversely, CXCR4 is more
highly expressed on naı ¨ve CD4
+ T cells than it is on memory
CD4
+ T cells [14], making kN4&kM4.
Generalized conditions for an and am. HIV is associated
with increasing levels of CD4
+ T cell activation [23,28,29,30].
Curve fitting in vivo data from [23], Ribeiro et al. [18] found that
the fractions of phenotypically-activated (Ki67
+) naı ¨ve (an) and
memory CD4
+ T cells (am) have the following inverse relationships
to the total CD4
+ T cell count per microliter (denoted CD4 in the
equations below):
an(CD4)~
10
CD4
{:0095
am(CD4)~
10
CD4
z:05
ð1Þ
Rather than restrict ourselves to an analysis based on Eq. (1), we
only assume that an and am obey three general conditions for all
CD4
+ T cell counts:
i) an(CD4)vam(CD4)
ii) an
0(CD4)v0,am
0(CD4)v0 ð2Þ
iii)
d
dCD4
an(CD4)
am(CD4)

v0
In other words, i) the fraction of activated cells is assumed to
always be higher among memory CD4
+ T cells than among
naı ¨ve CD4
+ T cells, ii) both fractions are assumed to be
increasing as CD4
+ T cell counts decline, and iii) as CD4
+ T
cells are depleted, the fraction of activated naı ¨ve CD4
+ T cells
increases relative to the fraction of activated memory CD4
+ T
cells. Importantly, the relative fraction an/am can increase even
when an increases at a slower rate than am in response to CD4
+ T
cell decline.
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A Single Compartment Model Generates an R5 to X4
Switch without Coexistence
In single target-cell compartment susceptible-infectious (SI)
models such as Model 1, the ecological principle of competitive
exclusion generally applies [31]. Thus, while Model 1 can produce
an R5 to X4 switch in a clinically representative timeframe, it
necessarily manifests competitive exclusion (Fig 1a). The lack of
steady-state coexistence in Model 1 is significantly different from
data, which show long-term coexistence of R5 and X4 variants in
post-switch individuals [32]. Moreover, X4’s emergence late in
infection—well into quasi-steady state—is very difficult to achieve
in this single compartment framework, because X4 could have
been rendered extinct via competitive exclusion prior to the late-stage
switch (Weinberger and Perelson, manuscript in preparation).
Two Target Cell Populations Can Produce R5 and X4
Coexistence
In order to prevent the species with the higher effective
reproductive ratio from dominating exclusively, which contradicts
observed results [32], Model 2 splits the target cell population into
naı ¨ve and memory CD4
+ T cells, and, for simplicity, assumes that
X4 solely infects naive cells and that R5 only infects memory cells.
The dual-target cell compartment nature of Model 2 makes
Figure 1. Models assuming a single target-cell population for X4 and R5, and models where X4 and R5 infect distinct populations
cannot account for X4 and R5 data. (A) A pedagogical model (schematic and numerical simulations) that is oversimplified to account for only a
single target-cell population generates a competitively exclusive R5-to-X4 switch where R5 virus is cleared (i.e. goes extinct) following the switch,
contrary to in vivo data [32]. The model simulates a ‘‘phenotypic’’ switch occurring at a clinically representative time of 3–4 years post HIV-1 infection,
and, notably, yields a concomitant decline in CD4
+ T cell counts. The parameters used are l=33 cells/(mlNday), c=23/day, p=5750/day, d=0.7/day,
k4=5N10
24 ml/(virionsNday), and k5=10
24 ml/(virionsNday). (B) A model restricting R5 and X4 to disparate target cell compartments can generate a
clinically representative R5 to X4 switch over a large parameter regime and also exhibit coexistence of R5 and X4 post-switch. However, as shown in
(C), such models cannot account for in vivo data showing that R5 inhibitors increase X4 levels [19]. In (C), we apply a CCR5 blocker with a drug efficacy
of 0.9, starting at t=180 days. The model restricts R5 and X4 to independent target cell compartments, and, given the absence of viral competition,
always generates strong suppression of X4 in response to CCR5 inhibition. Simulations in (B) and (C) are shown for a representative parameter
regime: l=33 cells/(mlNday), c=23/day, p=2000/day, f=0.8, d=0.5/day, k4=0.0012 ml/(virionsNday), and k5=0.0034 ml/(virionsNday).
doi:10.1371/journal.pcbi.1000467.g001
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preparation). Thus, while Model 2 can also produce an R5-to-X4
switch at a clinically representative time, it is able to maintain R5
and X4 coexistence post-switch (Figure 1B).
However, CCR5 inhibition cannot produce a transient increase
in X4 (Figure 1C). This is because in models that restrict X4 and
R5 to infecting distinct target cell populations (e.g., Model 2), X4
does not infect any of the (memory) CCR5
+ T cells that are made
refractory to R5 infection by CCR5 inhibition. Quantitatively, Eq.
(2) stipulates an9(CD4),0, so when CCR5 is inhibited and
memory CD4
+ T cell counts rise, an decreases and the rate of
viral production from an X4-infected cell (p*an) is lowered. Due to
the lack of competition, the number of X4-infected cells does not
increase to compensate for the decreased per-cell virion produc-
tion rate, so X4 viral loads decrease (Figure S1). This result is in
contrast to recent studies on dually-infected rhesus macaques and
humans, which demonstrate clear increases in X4 virus after R5
virus is selectively suppressed through the use of a CCR5 inhibitor
[19,20]. To produce a temporal X4 increase upon R5 inhibition
and to maintain coexistence in contradistinction to Model 1, we
need a multi-compartment model where X4 infects both naı ¨ve and
memory CD4+ T cells.
Two Target Cell Compartments with Viral Competition
Allow Coexistence and Match Existing Data
In Model 3, our final and most biologically detailed model, we
include naı ¨ve and memory CD4
+ T cell compartments. Since
CXCR4 is found on a large number of memory CD4
+ T cells, we
allow for X4’s infection of memory as well as naı ¨ve CD4
+ T cells
(Figure 2A). Thus, Model 3 serves as a union of the two previous
models: it includes the X4 and R5 strain competition found in
Model 1 and it also includes the separate target cell compartments
of Model 2, which allowed for X4’s persistence prior to a switch
and the coexistence of strains afterward. Model 3 produces X4-to-
Figure 2. A model with two target-cell populations and viral competition in one of these populations matches in vivo data and
predicts that R5 inhibitors accelerate AIDS onset. (A) A schematic of Model 3, a competitive model with two target-cell populations. (B) The
model exhibits a coreceptor switch at approximately 1000–1400 days post-infection in two types of parameter regimes: the ‘‘non-competitive
regime’’ in (B, upper panel) and the ‘‘competitive regime’’ (B, lower panel). For the ‘‘non-competitive regime,’’ parameter values are: l=33 cells/
(mlNday), c=23/day, p=2100/day, f=0.8, d=0.5/day, kN4=0.00108 ml/(virionsNday), kM4=4N10
25 ml/(virionsNday), and kM5=0.0068 ml/(virionsNday),
while in the ‘‘competitive regime’’ we change kM4 to 5N10
24 ml/(virionsNday) and kN4 to 0.001 ml/(virionsNday) (decreased in order to keep X4 in check).
(C) The net effect of a CCR5 inhibitor with 80% efficacy on the time to AIDS across different kM4 and kM5 levels (i.e. different competitive and non-
competitive regimes). AIDS onset is defined as the time at which CD4
+ T cell counts fall below 200 cells/ml: negative values represent accelerated
times to AIDS-onset relative to no treatment. R5 inhibitors clearly accelerate AIDS-onset for a large fraction of parameter space. (D) Time-dependency
of X4 emergence as a function of CCR5 inhibitor efficacy (a-CCR5 efficacy) in the ‘‘competitive regime.’’ Increased CCR5 inhibitor efficacy accelerates
X4 emergence and increases X4’s viral set point.
doi:10.1371/journal.pcbi.1000467.g002
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and also maintains coexistence post-switch in two types of
parameter regimes, the ‘‘non-competitive’’ and ‘‘competitive’’
regimes, whose distinctions are elaborated upon below (Figure 2B).
Given that X4 and R5 viruses can coexist in the disjoint two-
compartment model, it is reasonable to conjecture that coexistence
is a feature of this extended model as well. To show this formally,
we define Reff4 and Reff5 to be the effective reproductive ratios of X4
and R5 virus, respectively, which are given by:
Reff4(t)~p   (an(CD4(t)   kN4   N(t)zam(CD4(t))   kM4   M(t))=(c   di)
Reff5(t)~p   (am(CD4(t))   kM5   M(t))=(c   di)
Reff4=Reff5(t)~(kN4=kM5)   (an(CD4(t))=am(CD4(t)))   (N(t)=M(t))zkM4=kM5
ð3Þ
The effective reproductive ratio, Reff, is thus a time-dependent
function for the average number of infected cells produced by an
average infected cell at a given point, t, in time. Reff generalizes R0,
the basic reproductive ratio, which evaluates the average infectivity
only at the initial time point.
Solving the necessary and sufficient conditions for an R5-to-X4
switch, d/dt(V4(t*)).d/dt(V5(t*)) and V4(t*)=V5(t*), we see that a
switch occurs in Model 3 if and only if:
(an(CD4(t1))=am(CD4(t1)))w(M5(t1)-M4(t1))=N4(t1) ð4Þ
But am.an for all time, so, in particular, at the switch time t* we
have an(CD4(t*))/am(CD4(t*)),1. The right-hand side of Equation
(4) must therefore be less than 1, meaning that at the switch point
N4(t*)+M4(t*).M5(t*). Thus, at the switch point t* there are more
X4-infected CD4
+ T cells than R5-infected CD4
+ T cells. This
implies that X4 had a higher effective reproductive ratio at some
earlier point, t**. However, Reff4 (t**).Reff5 (t**) does not imply
that Reff4 (t).Reff5 (t) for all t.t**: Equation (3) implies that when N
decreases faster than M and when the resulting decrease to N/M is
less than the increase to an/am,R eff5 increases relative to Reff4 (i.e.,
Reff4/Reff5 decreases). But the condition for steady-state coexistence
of X4 and R5 is Reff4=R eff5, so by enabling Reff5 to rebound relative
to Reff4 post-switch, the dual-compartment nature of Model 3
makes coexistence possible.
We can grasp the switch threshold in (4) more easily by
substituting in the particular equations of (1), yielding the following
switch condition (where the right-hand side is positive):
CD4(t1)v200
N4(t1)zM4(t1){M5(t1)
M5(t1){M4(t1)z:19N4(t1)
ð5Þ
Importantly, Equations (3) and (5) imply that, with the exception
of changes to kM5, modulating parameters to accelerate CD4
+ T
cell decline hastens an R5 to X4 switch while changing parameters
to mitigate CD4
+ T cell decline hinders a phenotypic switch. Thus,
successful antiretroviral therapy will generally inhibit X4’s
emergence. However, because R5 and X4 are now in competition,
CCR5 inhibitors generate more complicated kinetics.
CCR5 Inhibitors Can Accelerate X4 Emergence: The Need
for CXCR4 Inhibitors or HAART
CCR5 inhibitors decrease kM5, causing R5’s viral load to
decline, and, as a result, memory CD4
+ T cell counts to increase.
The question we sought to answer is whether X4 infects
sufficiently many of these R5-immune memory CD4
+ T cells to
counteract the increase in CD4
+ T cells from CCR5 inhibition.
We hypothesized that X4’s ability to infect memory CD4 T cells
would depend on kM4, and with a sufficiently large kM4 (the
‘‘competitive regime’’), X4 would infect a non-negligible fraction
of newly R5-immune cells which and an increase in X4 would
ensue. The temporal increase in X4 viral loads would thus cause
greatly increased X4 infection of naı ¨ve CD4
+ T cells, which yields
accelerated naı ¨ve CD4
+ T cell depletion. Indeed, numerical
simulations (Text S1 contains more information on how these
simulations were done) show that successful CCR5 blockage
results in accelerated AIDS onset across much of parameter space
(Figure 2C). This result does not change when Model 3 is extended
to include the loss of virions due to the infection of new target cells
(Figure S2). Importantly, the early immunodeficiency after
effective CCR5 blockage is due to accelerating X4 emergence
and increasing X4 viral loads as the efficacy of CCR5 inhibition
increases in the ‘‘competitive regime’’ (Figure 2D).
Conversely, if kM4 is sufficiently small (the ‘‘non-competitive
regime’’), X4 does not infect a sufficient number of dually-positive
memory CD4
+ T cells upon CCR5 blockage. This causes the
uninfected memory CD4
+ T cell population to increase during
anti-CCR5 therapy, yielding a drop in an/am and hindering a
potential switch to X4 as well as immunodeficiency (Figure 2C,
small kM4 regime). The latter result is to be expected from Model
2, because a weak kM4 can be approximated by a complete lack of
competition. Thus, a single parameter, kM4, controls the efficacy of
anti-CCR5 therapy in dually infected HIV patients, highlighting
the need for circumspection in prescribing these treatments.
Given that CCR5 inhibitors accelerate R5-to-X4 switching and
immunodeficiency across the wide swath of parameter space in
which kM4 is relatively large, the question arises as to whether
CCR5 inhibitors are similarly deleterious when used in conjunc-
tion with CXCR4 inhibitors, which reduce kM4. Simulations show
that adding a CXCR4 inhibitor with an efficacy of at least 5% is
sufficient to prevent accelerated AIDS onset in the ‘‘competitive
regime’’ (Figure 3A). Because X4 emergence is due to an increase
in the relative fraction an/am of activated naı ¨ve to memory CD4
+ T
cells, we also simulated whether a generic antiretroviral therapy
such as HAART, which increases CD4
+ T cell counts and reduces
an/am, also prevents the accelerated X4 emergence that CCR5
inhibitors can engender. The results of dual-treatment with
HAART and CCR5 inhibitors are analogous to those shown for
dual-treatment with CXCR4 and CCR5 inhibitors, proving that a
relatively modest additional HAART therapy (with an efficacy
above 7%) obviates the risk of CCR5 inhibitors accelerating
immunodeficiency in the ‘‘competitive regime’’ (Figure 3B).
Finally, generalizing across kM4 and kM5 parameter space shows
that when treatment efficacies are sufficiently strong (e.g. 80%
efficacies) dual treatment with CXCR4 inhibitors does not
accelerate immunodeficiency relative to untreated individuals
(Figure 3C). Similarly, dual-treatment with CCR5 inhibitors and
HAART does not accelerate immunodeficiency relative to
untreated individuals (Figure 3D).
Discussion
Here we present a mathematical model of dual-strain R5 and
X4 HIV in vivo dynamics and show that CCR5 inhibitors can
accelerate the emergence of X4 virus and immunodeficiency. Two
equivalent R5-to-X4 switch conditions were found: either the ratio
of the relative fractions of activated naı ¨ve and memory CD4
+ T
cells (an/am) must surpass a threshold (Eq. 4) or, equivalently,
CD4
+ T cell counts must drop below a critical value (Eq. 5). The
resultant ‘‘phenotypic’’ switch yields a drastic loss in CD4
+ T cell
counts, due to X4’s depletion of R5-immune naı ¨ve CD4
+ T cells.
Of significant clinical importance, our results show that, across
much of parameter space, CCR5 inhibitors may force an early
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+ T cell depletion and
AIDS onset. However, CCR5 inhibitors do not appear to have the
deleterious effect of accelerating X4 emergence and immunode-
ficiency when they are used in conjunction with CXCR4
inhibitors or HAART.
The result that CCR5 blockers alone may promote X4
emergence is supported by data from a study on dually-infected
rhesus macaques injected intravenously with the CCR5 inhibitor
CMPD 167 [19]. After beginning treatment, two out of three
primates manifested a transient increase of several logs in X4 viral
load, essentially canceling the decrease in R5 viral load. Moreover,
a clerical error in a recent study on the effect of the CCR5
inhibitor maraviroc on R5-only patients resulted in a dually-infected
patient mistakenly being included in the trial [33]. That patient
saw no change in total viral load as the X4 viral load increased
upon CCR5 inhibition [20].
While CCR5 inhibitors alone may accelerate X4 emergence
and AIDS onset, there is still good reason to consider their utility
as part of a multi-therapy cocktail. Recent clinical data from the
MOTIVATE 1&2 trials show that CCR5 inhibitors together with
optimized background therapy yield larger increases in CD4
counts and larger reductions in viral loads when compared with
optimized background therapy alone [34]. Our model simulations
strongly support this result, showing that across much of
parameter space, employing CCR5 inhibitors together with
HAART lengthens the time to AIDS when compared with the
time to AIDS under HAART alone (Figure S3).
But even if CCR5 inhibitors are a helpful component in a
diversified anti-HIV therapy, one has to wonder about the greater
immunological cost associated with blocking this chemokine
receptor. A recent meta-population analysis of West Nile Virus
(WNV) prevalence in four US states found that CCR5D32
homozygotes are approximately four times more likely to develop
symptomatic WNV as are those with the wild-type receptor [35].
Previous murine models have suggested a mechanism by which
CCR5 confers protective advantage against symptomatic WNV:
CCR5 may promote the transfer of leukocytes to a WNV-infected
individual’s brain, aiding in immune control of encephalitis [36].
CCR5’s potential protective advantage against symptomatic WNV
may also help explain why CCR5D32/D32 is relatively common
Figure 3. Combination treatment with HAART or CXCR4 inhibitors can prevent CCR5 inhibitors from accelerating AIDS-onset. (A)
CXCR4 inhibitors with an efficacy of at least 5% prevent CCR5 inhibitors from accelerating time to AIDS in the ‘‘competitive regime.’’ Relative to no
treatment, the net time to AIDS onset is positive (i.e. AIDS onset is never accelerated) for any CCR5 inhibitor accuracy if CXCR4 inhibitors have an
accuracy of at least 10%. (B) Similarly, HAART with an efficacy of at least 7% prevents CCR5 inhibitors from accelerating time to AIDS (i.e., having a
negative net time) in the competitive regime. (C) Net time to AIDS with dual-treatment using CCR5 and CXCR4 inhibitors, each with 80% efficacy,
across different values of kM4 and kM5 relative to no treatment. The net time to AIDS onset is never negative for dual treatment with CCR5 and CXCR4
inhibitors (i.e. AIDS onset never accelerated) when the inhibitors have strong efficacies. (D) The net effect of dual-treatment with CCR5 inhibitors and
HAART, each at 80% efficacy, on the time to AIDS at different values of kM4 and kM5. The net time to AIDS onset is never negative for dual treatment
with CCR5 inhibitors plus HAART (i.e. AIDS onset never accelerated) when the inhibitors and HAART have strong efficacies.
doi:10.1371/journal.pcbi.1000467.g003
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African populations [37], the latter being at a far greater risk of
contracting WNV.
Additionally, it is important to consider the prospect that CCR5
inhibition may lead to HIV evolving to bind to an entirely new
coreceptor during early infection. A precedent for the evolution of
new lentiviral coreceptor tropisms exists: the SIV endemic to red-
capped mangabeys (RCMs) can utilize CCR2b rather than CCR5
[38]. This is likely because a large percentage (estimated at over
80%) of RCMs are homozygous for a 24 base-pair deletion in the
gene for CCR5, and CCR5D24/D24 cells cannot be transfected
with R5 virus [38]. The ability of SIVrcm to use CCR2b occurs
despite almost all other known SIVs utilizing CCR5 exclusively in
vivo [5]. D24 appears to be an ancient deletion: it has been found in
both red-capped mangabeys and sooty mangabeys, species which diverged
more than 10,000 years ago [38]. It is therefore possible that in the
long-run HIV may evolve entirely new coreceptor usages in
response to coreceptor inhibition.
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